IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9932400 B1

PDFFull Text
Date of Patent:
Apr. 03, 2018

Filed:

Aug. 20, 2014

Bi-specific monovalent diabodies that are capable of binding to gpa33 and cd3, and uses thereof

Applicant:

Macrogenics, Inc., Rockville, MD (US);

Inventors:

Paul A. Moore, Bethesda, MD (US);

Jonathan Li, Millbrae, CA (US);

Francine Zhifen Chen, San Francisco, CA (US);

Leslie S. Johnson, Damestown, MD (US);

Kalpana Shah, Boyds, MD (US);

Ezio Bonvini, Potomac, MD (US);

Assignee:

MacroGenics, Inc., Rockville, MD (US);

Attorneys:

William C. Schrot

AuerbachSchrot LLC

Primary Examiner:

Nelson B Moseley, II

Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/3046 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/56 (2013.01); C07K 2317/624 (2013.01); C07K 2317/626 (2013.01); C07K 2317/64 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/31 (2013.01);
Abstract

The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a 'gpA33×CD3 bi-specific monovalent diabody'). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain ('bi-specific monovalent Fc diabodies') and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33×CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.

Find Patent Forward Citations

Loading…